November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Toni Choueiri on the Flexibility of Therapies Beyond PD-1 Inhibitors
Nov 9, 2024, 20:04

Toni Choueiri on the Flexibility of Therapies Beyond PD-1 Inhibitors

Toni Choueiri, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, shared on X:

“SUPP FIG 2 tells it all—an example we worked on taking KYN564 as an example. Subsequent therapies can be ‘many things’ and does not need to be a PD-1 inhibitor.”

Toni Choueiri on the Flexibility of Therapies Beyond PD-1 Inhibitors

Toni K. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School.

As a medical oncologist, clinical trialist, and translational researcher, he specializes in treating genitourinary cancers (prostate, bladder, testis, and kidney cancer), with a focus on kidney cancer.